Institution
Ford Motor Company
Company•Dearborn, Michigan, United States•
About: Ford Motor Company is a company organization based out in Dearborn, Michigan, United States. It is known for research contribution in the topics: Internal combustion engine & Clutch. The organization has 36123 authors who have published 51450 publications receiving 855200 citations. The organization is also known as: Ford Motor & Ford Motor Corporation.
Topics: Internal combustion engine, Clutch, Control theory, Torque, Exhaust gas
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the authors address realistic subjects encountered in the challenge of achieving technology improvement in a vehicle stability control system, including driver intent recognition, vehicle status measurement and estimation, control target generation, system actuation efficiency and smoothness, road bank angle detection, system development and evaluation, and fault detection.
Abstract: Addresses realistic subjects encountered in the challenge of achieving technology improvement in a vehicle stability control system. They include driver intent recognition, vehicle status measurement and estimation, control target generation, system actuation efficiency and smoothness, road bank angle detection, system development and evaluation, and fault detection.
234 citations
TL;DR: In this paper, a technoeconomic analysis was conducted for metal-organic framework (MOF) adsorbents, which are promising candidates for light-duty vehicle on-board natural gas and hydrogen storage.
Abstract: A techno-economic analysis was conducted for metal–organic framework (MOF) adsorbents, which are promising candidates for light-duty vehicle on-board natural gas and hydrogen storage. The goal of this analysis was to understand cost drivers for large-scale (2.5 Mkg/year) MOF synthesis and to identify potential pathways to achieving a production cost of less than $10/(kg of MOF). Four MOFs were analyzed with four different metal centers and three different linkers: Ni2(dobdc) (dobdc4– = 2,5-dioxido-1,4-benzenedicarboxylate; Ni-MOF-74), Mg2(dobdc) (dobdc4– = 2,5-dioxido-1,4-benzenedicarboxylate; Mg-MOF-74), Zn4O(bdc)3 (bdc2– = 1,4-benzenedicarboxylate; MOF-5), and Cu3(btc)2 (btc3– = 1,3,5-benzenetricarboxylate; HKUST-1). Baseline costs are projected to range from $35/kg to $71/kg predicated on organic solvent (solvothermal) syntheses using an engineering scale-up of laboratory-demonstrated synthesis procedures and conditions. Two alternative processes were analyzed to evaluate the cost impact of reducing so...
233 citations
TL;DR: It is demonstrated that administration of PROG to the male rat before or 2 hours after onset of MCAO reduces ischemic cell damage and improves physiological and neurological function 2 days after stroke, suggesting potential therapeutic properties of PROG in the management of stroke.
233 citations
TL;DR: In this paper, the effects of sea-salt-aerosol pH on oxidation processes, sulfur cycling, and surface-ocean fertilization are investigated under clean and polluted conditions, and the relative contribution of H 2 SO 4(g) scavenging to S (VI) in sea salt increases with decreasing pH.
233 citations
Austrian Institute of Technology1, Johns Hopkins University2, Utrecht University3, Ford Motor Company4, Bar-Ilan University5, ReNeuron6, Karolinska Institutet7, Salk Institute for Biological Studies8, Paracelsus Private Medical University of Salzburg9, National Tsing Hua University10, Royal Brisbane and Women's Hospital11, Hiroshima University12, National University of Singapore13, Tufts University14, Guangzhou Institutes of Biomedicine and Health15, Agency for Science, Technology and Research16, Tsinghua University17, University of Duisburg-Essen18
TL;DR: A review outlines topic‐specific action items that, if addressed, will enhance the development of best‐practice models for EV therapies and help to standardization and coordination of development efforts.
Abstract: Growing interest in extracellular vesicles (EVs, including exosomes and microvesicles) as therapeutic entities, particularly in stem cell-related approaches, has underlined the need for standardization and coordination of development efforts. Members of the International Society for Extracellular Vesicles and the Society for Clinical Research and Translation of Extracellular Vesicles Singapore convened a Workshop on this topic to discuss the opportunities and challenges associated with development of EV-based therapeutics at the preclinical and clinical levels. This review outlines topic-specific action items that, if addressed, will enhance the development of best-practice models for EV therapies. Stem Cells Translational Medicine 2017;6:1730-1739.
232 citations
Authors
Showing all 36140 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Anil K. Jain | 183 | 1016 | 192151 |
| Markus Antonietti | 176 | 1068 | 127235 |
| Christopher M. Dobson | 150 | 1008 | 105475 |
| Jack Hirsh | 146 | 734 | 86332 |
| Galen D. Stucky | 144 | 958 | 101796 |
| Federico Capasso | 134 | 1189 | 76957 |
| Peter Stone | 130 | 1229 | 79713 |
| Gerald R. Crabtree | 128 | 371 | 60973 |
| Douglas A. Lauffenburger | 122 | 705 | 55326 |
| Abass Alavi | 113 | 1298 | 56672 |
| Mark E. Davis | 113 | 568 | 55334 |
| Keith Beven | 110 | 514 | 61705 |
| Naomi Breslau | 107 | 254 | 42029 |
| Fei Wang | 107 | 1824 | 53587 |
| Jun Yang | 107 | 2090 | 55257 |